2017 / 02

Next Paper
DOI: 10.24075/brsmu.2017-02-08

ORIGINAL RESEARCH

Effectiveness and safety of treatment with domestic cepeginterferon alpha-2b in patients with chronic hepatitis C infection. Actual clinical experience

Tkacheva SV1, Manapova ER1, Sozinova YuM1,2, Yakupova FM1,2, Fazylova YuV3
About authors

1 Department of Infectious Diseases, Faculty of Medical and Preventive Care,
Kazan State Medical University, Kazan, Russia

2 Diagnostic and Consultation Unit,
Agafonov Republican Clinical Hospital of Infectious Diseases, Kazan, Russia

3 Department of Dental Therapy, Faculty of Dentistry,
Kazan State Medical University, Kazan, Russia

Correspondence should be addressed: Svetlana Tkacheva
ul. Butlerova, d. 49, Kazan, Russia, 420012; ur.liam@umgk-avehcakt

About paper

All authors' contribution to this work is equal: selection and analysis of literature, planning of the manuscript's structure, data interpretation, drafting of the manuscript, editing.

Received: 2017-02-09 Accepted: 2017-03-10 Published online: 2017-06-02
|
  1. European Association for Study of Liver. Recommendations on Treatment of Hepatitis C 2015. J Hepatology. 2015 Jul; 63 (1): 199–236. DOI: 10.1016/j.hep.2015.03.025.
  2. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol’nykh gepatitom C (Letter of the Ministry of Health of the Russian Federation No. 17-00-6444 from 03.09.2014). Moscow, 2014. 91 p. Russian.
  3. Enaleeva DSh, Fazylov VKh, Sozinov AS. Khronicheskie virusnye gepatity В, С i D: rukovodstvo dlya vrachey. Moscow: GEOTAR- Media; 2015. 192 p. Russian.
  4. Pavlov AI, Kirillov SM, Ponomarenko DS, Havanshanov AK, Fadina JV, Bobkova IV, et al. [Efficacy and safety of сepeginterferon alfa- 2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice]. Journal Infectology. 2016; 8 (3): 92–8. DOI: 10.22625/2072-6732-2016- 8-3-92-98. Russian.
  5. Mayevskaya MV, Znoyko OO, Klimova EA, Maximov AS, Kizhlo SN, Petrochenkova NA, et al. [Efficacy of pegylated interferon alfa- 2b «Algeron» in the treatment of chronic hepatitis C]. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013; 23 (1): 30–6. Russian.
  6. Mayevskaya MV, Znoyko OO, Klimova EA, Maximov AS, Kizhlo SN, Petrochenkova NA, et al. [Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin (Final results of randomized comparative clinical study)]. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014; 24 (2): 53–64. Russian.
  7. Blokhina NP, Nurmuhametova EA, Rusanova MG, Gagarina IV, Mar’jamova ES, Kuznetsova NA, et al. [The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice]. Journal Infectology. 2016; 8 (2): 48–55. Russian.
  8. Znoyko O, Mayevskaya MV, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Rapid and early virologic response to сepeginterferon-alfa-2b in combination with ribavirine in treatment-naïve patients with chronic HCV. Hepatology. 2012; 56 (4 Suppl 1): 586A.
  9. Znoyko O, Maevskaya M, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Early virologic response (EVR) in treatment-naive mono-infected chronic hepatitis C (CHC) patients treated with cepeginterferon-alfa-2b (cePEG-IFNa-2b) plus ribavirin. J Hepatology. 2013; 58 (Suppl 1): S348–9.
  10. Znoyko O, Maevskaya M, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Сepeginterferon-alfa-2b combination with ribavirin in treatment-naive patients with chronic hepatitis С. J Hepatology. 2014; 60 (Suppl 1): S476.
  11. Znoyko OO, Linkova YuN, Morozova MA. Klinicheskiy opyt primeneniya skhemy troynoy terapii, vklyuchayushchey tsepeginterferon al'fa-2 b, simeprevir i ribavirin, u patsientov s khronicheskim gepatitom C genotipa 1. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2016; (2): 100–9. Russian.